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ABSTRACT
Advances in stem cell research have triggered scores of studies in regenerative medicine in a large
number of institutions and companies around theworld. However, reproducibility anddata exchange
among laboratoriesor cell banksare constrainedby the lackofa standardized format for experiments.
To enhance information flow in stem cell and derivative cell research, here we propose a minimum
information standard to describe cellular assay data to facilitate practical regenerative medicine.
Based on the existing Minimum Information About a Cellular Assay, we developed Minimum Infor-
mation About a Cellular Assay for Regenerative Medicine (MIACARM), which allows for the descrip-
tion of advanced cellular experimentswith defined taxonomyof human cell types. By using controlled
terms, such as ontologies, MIACARMwill provide a platform for cellular assay data exchange among
cell banks or registries that have been established at more than 20 sites in the world. STEM CELLS
TRANSLATIONAL MEDICINE 2016;5:1345–1361
SIGNIFICANCE
Currently, there are more than 20 human cell information storage sites around the world. However,
reproducibility anddata exchange amongdifferent laboratories or cell information providers are usu-
ally inadequate or nonexistent because of the lack of a standardized format for experiments. This
study, which is the fruit of collaborative work by scientists at stem cell banks and cellular information
registriesworldwide, including those in theU.S., theU.K., Europe, and Japan, proposes newminimum
information guidelines, Minimum Information About a Cellular Assay for Regenerative Medicine
(MIACARM), for cellular assay data deposition. MIACARM is intended to promote data exchange
and facilitation of practical regenerative medicine.
INTRODUCTION
The invention of human embryonic stem (hES) cells
in 1998 [1], followed by human inducedpluripotent
stem (hiPS) cells in 2007 [2], have spearheaded new
developments in regenerativemedicine around the
world. A number of large-scale initiatives have
been funded to make research- and clinical-
grade hES and hiPS cell resources widely avail-
able to the global community [3]. Before clinical
application, however, quality checks must be
carried out to prove that artificially generated
pluripotent stem cells and their differentiated
cells can be used to form the basis for safe and
effective cell therapies. To control the quality
of engineered cells, assay data must be compa-
rable to those of naturally existing cells in a de-
fined format.
The data accumulation or exchange format
must be capable of handling advanced experi-
mental techniques with higher resolutions. Re-
cently, next-generation sequencing techniques,
in addition to use in the analysis of genome var-
iation and the presence of virus sequences, are
being applied to transcriptome and methylome
analyses. In addition, cellular assays often de-
mand single-cell resolution for quality checks. In-
deed, it has been reported that, even in cells
extracted from a single colony, the derivative cul-
tures may remain heterogeneous, whichmay well
have an impact on cell fate [4–7].
The accumulation of cellular assay data from
pluripotent stem cells and their derivatives has al-
readybegun in iPSorembryonic stem(ES) cellbanks
and registries around the world. Cellular informa-
tiongatheredbycellbanks isavailabletothegeneral
public. In contrast, cell registries collect cellular in-
formation from cell banks or laboratories and pro-
vide digital information through retrieval systems.
Fifteen well-known stem cell banks and registries
are listed in Table 1. The largest numbers of report-
edhESorhiPS cells fornormal anddiseased cells are
1,229 at the Human Induced Pluripotent Stem Cells
Initiative (HipSci, http://www.hipsci.org) in theU.K.
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and 373 at the International StemCell Registry of University ofMas-
sachusettsMedical School in theU.S. (http://www.iscr-admin.com),
respectively.
However, reproducibility and data exchange among cell
banks or laboratories are compromised because of the lack of a
standardized format for experiments. In order to exchange or in-
tegrate cellular assay information produced at different sites, not
only measurement data, but also the format of additional exper-
imental metadata, such as experimental design, sample informa-
tion, measurement techniques, measurement uncertainty, etc.,
Table 1. Examples of stem cell banks and registries (as of October 14, 2015)
Country Bank or registry Stem cell bank or registry No. of hES/hiPSC entries Website
EU B BLCB Normal: 33 http://www.cmrb.eu/
banco-lineas-celulares
R hPSCreg Normal: 730 http://hpscreg.eu
Diseased: 58
U.K. R HipSci Normal: 1229 http://www.hipsci.org
Diseased: 207





B EBiSC TBA http://www.ebisc.org
U.S. R CIRM Normal: 48 https://www.cirm.ca.gov/
B Coriell Institute Diseased: 300 https://catalog.coriell.org/1/
Stem-Cells
B Harvard Stem Cell Institute Normal: 23 http://stemcelldistribution.
harvard.eduDiseased: 3
Status unknown: 29
R NIH Stem Cell Database Normal: 21 https://stemcelldb.nih.gov/
public.do
B NYSCF Normal: 73 http://nyscf.org
Diseased: 113




B RUCDR Infinite Biologics Normal: 25 http://www.rucdr.org
NIMH Stem Cell Center Diseased: 332 https://www.nimhgenetics.
org/stem_cells




NIH CRM iPSC Collection http://www.nimhgenetics.
org/stem_cells/crm_lines.
php
Target ALS Foundation http://www.targetals.org
B WiCell Research Institute Normal: 69 http://www.wicell.org
Diseased: 2
JP B RIKEN BRC Cell Bank Normal: 16 http://cell.brc.riken.jp/en
Diseased: 320




Abbreviations: ALS, amyotrophic lateral sclerosis; B, bank; BLCB, StemCell Bank of Barcelona; BRC, BioResource Center; CIRM, California Institute for
RegenerativeMedicine; CRM,Center for RegenerativeMedicine; EBiSC, EuropeanBank for InducedPluripotent StemCells; EU, EuropeanUnion; hES,
human embryonic stem; hiPSC, human induced pluripotent stem cell; HipSci, Human Induced Pluripotent Stem Cells Initiative; hPSCreg, Human
Pluripotent StemCell Registry; iPSC, induced pluripotent stem cell; JP, Japan; NIMH, National Institute ofMental Health; NINDS, National Institute of
Neurological Disorders and Stroke; NYSCF, New York Stem Cell Foundation; R, registry; RUCDR, Rutgers University Cell and DNA Repository Infinite
Biologics; SKIP, Stemcell Knowledge and Information Portal; TBA, to be announced; UMass ISCR, University ofMassachusetts International StemCell
Registry.
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must be registered and rendered retrievable. Themoremetadata
that are collected, the more precisely cellular assay experiments
that are reproduced.However, this approachwill generate a com-
plex and redundant format, as well as require much space and
time for curation. For the efficient collection of necessary infor-
mation, it is vital to clarify minimum, yet indispensable, items
for structuring the data format by which cellular assay data can
be efficiently stored.
To solve this problem, Minimum Information (MI) Stan-
dards were invented as reporting guidelines for standardizing
data entities. The first of such guidelines,Minimum Information
About aMicroarray Experiment, was organized by international
consortia and established to integrate microarray data from
various platforms [8]. It was followed by theMinimum Informa-
tion About a Biomedical or Biological Investigation project in
2008 [9], which yielded approximately 80 MIs for various kinds
of biological assays. Because those guidelines usually target
simple phenomena in biological systems, several MIs may have
to be combined to function as guidelines for holistic descrip-
tions of cellular systems.
As the first attempt to enhance exchangeability of cellular as-
say data, Minimum Information About a Cellular Assay (MIACA)
was created in 2008 as a reporting format that mainly focused
on describing functional research using cell lines [10]. However,
it was not designed to describe human somatic cells or advanced
technologies for single-cell analysis. Moreover, for it to be appli-
cable to regenerative medicine, experimental itemsmust comply
with existing drug and medical regulations. By reorganizing and
extending MIACA, we developed Minimum Information About
a Cellular Assay for Regenerative Medicine (MIACARM), which
would allow for the description of advanced cellular experiments
with defined taxonomy of human cell types.
In Figure 1, a conceptual view of how MIACARM contributes
to stem cell research is shown. Our aim is to provide information
of assays anddata of all source cell types (somatic and engineered
cells) at the clinical level, by which regenerative medicine and
drug discovery can be conducted efficiently. In regenerativemed-
icine research, there exists Minimal Information About T Cell As-
says [11] for cell therapy and Bone/Cartilage Tissue Engineering
Ontology [12] for tissue engineering, whereas in drug discovery,
there existsMinimum Information required for a DrugMetaboliz-
ing Enzymes and Transporters Experiment [13] and Minimum In-
formation About a Bioactive Entity [14]. However, important
prerequisite information is lacking in these MIs, including how
source cells, such as stem or differentiated cells, are generated
by in vitro reprogramming or (trans)differentiation methods, as
well as detailed characteristics of the source cells. In cases where
the information does exist, it is described in free-text format. Re-
cently, many research groups have been working on creating
organoids for diseasemodeling, drug screening, and damaged tis-
sue repair [15]. However, organoids present variability in their
qualities, and, therefore, it is critical to check the detailed charac-
teristics of the source cells. MIACARM plays an important role in
ensuring that all safety and efficacy information is available for
actual medical situations by providing a list of items to exclude
ambiguously described assays and clarify data for cellular quality
and safety evaluation.
By using controlled terms, such as ontologies, MIACARM can
provide a platform for cellular assay data exchange among cell
banks, registries, or databases that havebeenestablishedatmore
than 20 laboratories or institutes around the world (Kurtz et al.,
manuscript in preparation). The first call forMIACARMwasmade
at the 2014 Mainz Symposium, “Cell-Focused Data: Integration,
Organization and Applications,” and the present paper contains
the first proposal to establish such a system.We expect that con-
tinuous international efforts will result in the further improve-
ment of MIACARM.
MATERIALS AND METHODS
Two Levels and Four Layers in MIACARM
We developed two levels of guidelines, MIACARM-I and -II.
MIACARM-I is the guideline for omics assays inbasic researchusing
humancells;MIACARM-II is theguideline for practical regenerative
medicine. Each guideline consists of a four-layered structure:mod-
ules, sections, subsections, and items, from top to bottom. Both
guidelines will basically contribute to the exchange, maintenance,
and reproducibility of cellular assay data.
Development of MIACARM Based on MIACA: Five
Modules and 15 Sections
Wefirst reorganizedtheexistingcellularassayguideline,MIACA[10],
and then developed a five-module structure consisting of Project,
Source Cell, Assay, Experimental Technology, and Data (Fig. 2) as
the top layer, based on the structure design of the Gene Expression
Omnibus (GEO) database [16], which consists of threemodules: Se-
ries, Sample, and Platform. We further divided Series of GEO into
Project and Assay, and Sample of GEO into Source Cell and Data,
to describe both the experimental protocols and information of
the cells in greater detail in MIACARM. MIACARM consists of 257
items, which are summarized and categorized in supplemental
online Table 1. As an extension of the MIACA structure, we also
added four new sections to the source cell module to MIACARM.
In MIACARM-I, we added subsections for Sequencing and
Marker Imaging Technology, which are absent in MIACA, to the
Experimental Technology module to enable the description of
current cell analysis devices. We also added two subsections to
the Source Cell module, Cell Taxonomy and Anatomical Location.
In MIACARM-II, we further added two more sections, Stem Cell
Production and StemCell Quality Control, to the Source Cellmod-
ule, according to two publications on stem cell banking [17, 18]
and four regulations for products from (stem) cells or tissues in
Japan, the U.S., and Europe [19–22]. To describe a single assay,
a set of four modules—Assay, Source Cell, Experimental Technol-
ogy, and Data—are required for reproducibility. Therefore, a sin-
gle project module may contain one or more sets of the four
modules to register multiple assays.
Ontology Assignment
To control proper curation terms in MIACARM, we collected
and assigned necessary IDs and technical and ontological terms
from 13 existing collections: BioAssay Ontology [23]; Cell: Ex-
pression, Localization, Development, Anatomy [24]; Chemical
Entities of Biological Interest Ontology [25]; Cell Ontology [26];
EDAM Bioinformatics Operations, Data Types, Formats, Identi-
fiers, and Topics [27]; Experimental Factor Ontology [28]; Bio-
logical ImagingMethodsOntology [29]; FoundationalModel of
Anatomy [30]; Medical Subject Headings [31]; Microarray and
Gene Expression Data Ontology [32]; National Cancer Institute
Thesaurus [33]; Ontology for Biomedical Investigations [34];
Uber Anatomy Ontology [35]; and PubMed/MEDLINE [36].
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The assignment of those IDs and terms to the five modules and
sections is summarized in supplemental online Table 1.
Evaluation of MIACARM
To evaluate how MIACARM reflects a realistic situation, we
checked for overlapping items in two sections of MIACARM-II,
Stem Cell Production and Stem Cell Quality Control, with the
web items used by the 11 stem cell banks and registries listed
in Table 1: Stem Cell Bank of Barcelona and Human Pluripotent
StemCell Registry in the EuropeanUnion; HipSci, andU.K. Stem
Cell Bank in the U.K.; California Institute for RegenerativeMed-
icine, the New York Stem Cell Foundation, the University of
Massachusetts International Stem Cell Registry, Rutgers Uni-
versity Cell and DNA Repository Infinite Biologics, and WiCell
in the U.S.; and Stemcell Knowledge and Information Portal
and RIKEN BioResource Center in Japan. Descriptive items
for cellular information provided by each website were col-
lected, and unique termswere computationally selected by us-
ing the XML library in R statistical language (https://www.
r-project.org).
RESULTS
Enhancement of Data Exchange and Comparability
Among Different Assays by MIACARM
MIACARM is designed to exchange assay information amongdif-
ferent experimental techniques. In particular, the new five-
module structure makes it easier to understand assays at the
level of materials and methods than does the three-module
structure in MIACA. As shown in Figure 3, we separate Reagent,
Instrument, and Cell Line from the subsection (Bio) Materials in
the Headermodule ofMIACA and combine themwith the Exper-
imental Modules of MIACA to generate the new Experimental
Technology module in MIACARM. By this reorganization, mate-
rial information and method information become independent,
and any experimental combination of Source Cell and Experi-
mental Technology can be produced, which enhances under-
standing of the whole experimental process. Similarly, the
Figure 2. Basic structure ofMIACARM: fivemodules and two levels
(I and II). By reorganizing the three-module structure of MIACA, we
adopted a five-module structure inMIACARM.MIACARM-I contains
the guideline for basic research, which includes omics assays using
human cells.MIACARM-II contains the guideline for practical regen-
erative medicine, which includes terms related to cell quality
checks. Abbreviations: MIACA, Minimum Information About a Cel-
lular Assay; MIACARM, Minimum Information About a Cellular As-
say for Regenerative Medicine; NGS, next-generation sequencing;
QC, quality control.
Figure 1. MIACARMenhances quality of stem cell research. In practicalmedicine, such as drug discovery, cell therapy, tissue engineering, etc.,
basedon stemcells or their derivatives,MIACARMprovides aprocedure for source cell production and source cell quality and safety information
to existing MIs. Abbreviations: BCTEO, Bone/Cartilage Tissue Engineering Ontology; DMET, Drug Metabolizing Enzymes and Transporters; iPS,
induced pluripotent stem; MI, minimum information; MIABE, Minimum Information About a Bioactive Entity; MIACA, Minimum Information
About a Cellular Assay;MIACARM,Minimum Information About a Cellular Assay for RegenerativeMedicine;MIATA,Minimal InformationAbout
T Cell Assays; MIDE, Minimum Information Required for a Drug Metabolizing Enzymes and Transporters Experiment.
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Project Description section in the Header module of MIACA is
separated at the subsection level into the Project and Assay
modules of MIACARM. This reorganization is especially impor-
tantwhen retrieving assays from a database. For example, when
searching for assays that use microarray technology, array
experiment-specific information, such as experimental condi-
tions, reagents, and instruments, can be found in the single Ex-
perimental Technology module in MIACARM, whereas those
Figure 3. Differences in modules and sections between MIACA and MIACARM. In contrast to the three-module structure in MIACA, a five-
module structure in MIACARM was developed to enhance the understanding of assays at the materials and methods level. Abbreviations:
MIACA, Minimum Information About a Cellular Assay; MIACARM, Minimum Information About a Cellular Assay for Regenerative Medicine;
PI, principal investigator.
Figure 4. Example of exchangeability and comparability of transcriptome, methylome, andmarker assays. The five-module structure (Project
module is not shown)makes it easy to search for various combinations of cell materials and experimental methods. Abbreviations: iPS, induced
pluripotent stem;MIACARM,Minimum Information About a Cellular Assay for RegenerativeMedicine; RT-PCR, reverse-transcription polymer-
ase chain reaction.
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would have to be retrieved from both the Header and Experi-
mental Modules in MIACA. Figure 4 shows how experiments
such as transcriptome, methylome, and marker assays are ex-
changeable and comparable. Overall, the new five-module
structure is user-oriented, because it makes searching for assays
consisting of various combinations of source cells and experimen-
tal methods easy.
MIACARM-II: Minimum Information for Stem
Cell Research
Various cell banks that generate and establish stem cell lines
have been launched worldwide. Cell registries that accumulate
digital information from those cell banks have been established
as well (Table 1). However, major issues regarding the workabil-
ity of the cell banks exist and are as follows: (a) there has been no
consensus on the quality evaluation of artificially generated
stem cells [17, 18], and, thus, (b) no standardized method is
available for establishing the highest-quality stem cells [37,
38]. A method for checking whether the established stem cells
are of researchor clinical grade is still under discussion, although
an international consensus on key issues for the establishment
of human pluripotent stem cell banks has been published [39].
Even more problematic is the fact that there are no minimum
information standards for describing the qualitative or quantita-
tive characteristics of established stemcells [40, 41],which ham-
pers comparisons between cell lines established in different
banks or laboratories.
Considering this situation, we first collected items to describe
theproduction procedures andquality checks of stemcells for the
“Source cell”module on the basis of six documents for the proper
management of cells [17–22] (Materials and Methods). Among
those items, we selected 144 items that are required to assess
product quality, safety, and efficacy, as indicated by the interna-
tional guidelines for medicines established in Japan, the U.S., and
Europe [42]. Table 2 shows the list of necessary items selected,
reference numbers, adoption status by stem cell banks and reg-
istries, and MIACARM levels. The items are divided into five cat-
egories: (a) produced stemcell summary, (b) ethical operation, (c)
material, (d) cell bankingprocess, and (e) cell characterization and
sterility testing.
Upon checking whether each of the 144 items is adopted by
the 11 stem cell banks and registries, we found that sterility test-
ing is adopted by most of the stem cell banks and registries.
However, many items considered important in practical medi-
cine, such as human leukocyte antigen type, single nucleotide
polymorphism (SNP), tumorigenesis, etc., are not open to the
general public, probably becauseof privacy issues. Furthermore,
information required for regulatory compliance for manufac-
ture of regenerative medicines, such as source cell information,
culture conditions, culture protocol, etc., are generally missing.
Importantly, we also found four items necessary for stem cell
information registration in which the reference is missing
(Table 2). Those four items are stem cell ID, date (stem cells)
placed in storage, subjected ethical approvals and accrediting
agencies involved, and reprogramming type in the stem cell es-
tablishment process. From the biobanking and repository per-
spective, it is critically important to use widely available short
tandem repeat (STR) or SNPTrace assays to unambiguously doc-
ument the identity of each biospecimen (source cell, hiPS cells,
differentiated cell lines, etc.) to address potential sample
mislabeling or swaps that can occur during sample collection
and processing [43]. Instances of such errors, which can have pro-
found and costly adverse effects on research studies, are well
documented [44].
Validating Items in MIACARM-II As
Minimum Information
To evaluate the selected minimum items in MIACARM-II, each
item in Table 2 is scored by counting the numbers of source ref-
erences and stem cell banks that adopted it. The results are
shown in Figure 5. Red lines indicate an arbitrary 20% threshold
of acceptance of items by either source references or stem cell
banks, and the four areas separated by the two lines are labeled
I–IV clockwise from the top left. The numbers of items in areas
I–IV are 18, 50, 75, and 1, respectively. When we examined the
independences of the item distributions by Pearson’s x2 test
with Yates’ continuity correction using chisq.test function in sta-
tistical computing language R, we found a probability of 2.6 3
1025 thatwas significantly low, and the probabilities of the stan-
dardized residuals for all areas were also significant (i.e., areas I
and III contain larger numbers of items, and areas II and IV con-
tain smaller numbers of items). In area II, the items that received
high scores from both source references and stem cell banks are
important in many fields of stem cell research and application.
Items in area I received high scores from stem cell banks and in-
cluded attributes associated with stem cell materials, such as
Stem Cell Name, Contact Information of Provider/Distributor
(Distribution Bank), and biological information of source cell do-
nor, such as Gender of Donor, Age of Donor When Source Cell
Was Obtained, and Informed Consent FromDonor. In particular,
all six items with high scores in box “a” are used for database
management rather than for describing the safety or quality
of thematerials, including StemCell ID, StemCell Name, Contact
Information of Generator, and Provider/Distributor (Distribu-
tion Bank). It is noteworthy that most items are distributed in
area III, where high scores are received from source references,
and are mainly about experimental materials used in the stem
cell culture and establishment. The three items in box b, which
received the highest scores from source references, comprise
two items, Basal Medium and Culture Additive and Concentra-
tion, related to the culture conditions of the source cells, and,
more important, one item, CopyNumber Variation (CNV), which
cannot be provided from the raw data provided by stem cell
banks because of privacy issues. Only HipSci provides sanitized
CNVdata by scatter plot. Finally, in area IV,which is the least sup-
ported by source references and stem cell banks, we observed
only one item, Single Nucleotide Polymorphisms (SNPs), in
MIACARM that considers cancer risks [45, 46] as safety informa-
tion for stem cells used as clinical products.
DISCUSSION
We propose for the first time a minimum information standard
to describe cellular assay data for the facilitation of practical re-
generativemedicine. This proposalwasmadeon thebasis of the
presentations delivered at the 2014 Mainz Symposium, “Cell-
Focused Data: Integration, Organization and Applications,”
and serves as a starting point for promoting international con-
tributions toward its further development. Based upon the
existing MIACA, we developed MIACARM, which is expected
1350 Minimum Information Guidelines for Stem Cell Banks
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to enable (a) thedescriptionofadvancedcellularexperimentswith
defined taxonomy of human cell types and controlled terms
(MIACARM-I), and (b) the description of production procedures
and quality checks of stem cells (MIACARM-II). MIACARM is
expected to provide a platform for cellular assay data exchange
among cell banks or registries around the world. Furthermore,
we anticipate several important regulatory advantages by adopting
MIACARM: (a) deposition of the minimum information and assay
metadata to reduce missing and unnecessary information about
the cells, (b) progress toward reproducible experiments, and (c) re-
trieval by omnibus search across all cell banks and registries in the
world.
Related Efforts and Paths to Optimize
Minimum Guidelines
Currently, there aremore than 20 human cell information storage
sites, such as banks, registries, and databases, in the world. How-
ever, reproducibility and data exchange among different labora-
tories or cell information storages are usually inadequate or
nonexistentbecauseof the lackof a standardized format for exper-
iments.Moreover, thestandardizationofcell-qualityevaluations in
relation to regenerative medicine products is still under discus-
sion. Despite the launch of the first clinical trial based on iPS cells
in Japan in 2014 [47], subsequent actions following that study
have been delayed, reflecting caution toward patient treatment.
This delay is expected given the current lack of standards for cell
preparation and assessment and little experience in stem cell
therapies. MIACARM is expected to contribute to the develop-
ment of comparative standards. Because MIACARM was devel-
oped on the basis of proposals and regulations in Japan, the
U.S., and Europe—the three jurisdictions involved in develop-
ment standards under the International Consensus on Harmoni-
zation—we expect it to mature and become a consensus
guideline that reflects practice of and advances in regenerative




































































































































































































































































































































































































































































































































































































































































































Figure 5. Evaluation of items in Minimum Information About a Cel-
lular Assay for Regenerative Medicine II (MIACARM-II). Items inMIA-
CARM-II are scored by counting the numbers of source references on
the basis of data in Table 2. Red lines indicate 20% threshold of accep-
tance by either source references or stem cell banks.
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research is the development of stem cell and cell line nomencla-
ture [40, 48–50]. Such nomenclature would be integrated into
MIACARM as a unique cell type name descriptor, which would re-
duce errors and confusion about the cells used in any experiments.
Recently, the draft “Guidelines for Stem Cell Science and Clinical
Translation” was proposed by the International Society for Stem
Cell Research [51]. However, this draft proposes guidelines toward
establishing regulatory rules.Conversely,discussionswithstemcell
expertsareneeded todetermine the items required for inclusion in
MIACARMas “minimum”mandatory informationanda framework
drafting for standardization issues from cell banking to the manu-
factured regenerative medicine product proposed by Stacey
(2014) [52]. To optimize MIACARM, we need to organize interna-
tional conventions on a periodic basis that draw consensus from
a broader range of experts involved in world stem cell bank regis-
tries.We should also bringMIACARM to the attention of the Inter-
national Organization of Standardization, currently beginning to
develop approaches to standards in regenerative medicine manu-
facturing, and the Organisation for Economic Co-operation and De-
velopment which is currently developing a new standard for good
in vitro methodology.
Flexibility to Incorporate Newly Developed Techniques
and Increasing Number of Cell Types
We have also developed a human cell repository database called
SHOGoiN (formerly CELLPEDIA [53]), wherewe curate gene expres-
sion data in a defined format using the MIACARM guideline. Re-
cently, more advanced experimental techniques at single-cell
resolution, including transcriptome, methylome, proteome, etc.,
have been reported. For example, the single-cell mass cytometry
assay can identify 18 types of hematopoietic cells on the basis of
surface antigens [54]. To enter those data, MIACARM must have
sufficient flexibility to incorporate newly developed techniques.
In addition, unidentifiable or new cell types have been found by
single-cell analysis [55]. Therefore, MIACARM must be sufficiently
flexible to dealwith the continuously increasing number of cell types.
In thefuture,anextendedMIACARMwouldberequiredformorepre-
cisedescriptionofother importantcellularassaysbasedonstemcells,
such as disease modeling, drug discovery, tissue engineering, etc.
CONCLUSION
One important issue to be resolved is how to handle and store
massive cell data. By using single-cell barcode technology,
thousands of cells are analyzed at one time tomeasureomics data
[56]. We expect to encounter millions of cell omics measure-
ment data, from which we need to retrieve only necessary in-
formation for particular cell types. To resolve the massive cell
data handling and storage issue, new computational systems,
such as distributed or cloud-type databases, are proposed by
bio-database sites in the world [57–59]. However, such distrib-
uted database systems require not only time and funding, but
also an international cooperation by a large number of consent-
ing researchers (Kurtz et al., manuscript in preparation). In any
case, extended MIACARM or completely new cellular assay
guidelines would be needed to support such systems in the
coming big data era.
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